Summary
47 / 100 · Bulios Score
What speaks for it
- Revenue grew by 24% a year over the last 3 years.
- It holds more cash than debt: $158.1M against $113.3M.
- The share price is below the Bulios Fair Price.
What to watch
- Operating profit does not even cover the interest on its debt.
- Earnings per share fell by 40% a year over the last 3 years.
- Out of every 100 USD of revenue, only 2.6 USD is left as net profit.
- It earns only 3.1 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 72.0 USD for 1 USD of yearly profit. Over the last five years it was 166.4 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 18% a year over 5 years. Over the last 3 years it grew by 24% a year. Earnings per share fell by 40% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 13 USD
- Research and development 31 USD
- Sales and administration 50 USD
- Taxes and other 3.0 USD
- Net profit 2.6 USD
Net profit, industry median (Biotechnology) -7.3 USD
Out of every 100 USD of revenue, 2.6 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 4.4 years of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 1
- Hold 0
- Sell 0
No analyst has published a price target.
100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.